Trial reportJournal of the American Heart Association2022
Time in Target Range for Systolic Blood Pressure and Cardiovascular Outcomes in Patients With Heart Failure With Preserved Ejection Fraction.
Trial report in Journal of the American Heart Association, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 48 citations in OpenAlex.
- Ambulatory blood pressure monitoring, European guideline targets, and cardiovascular outcomes: an individual patient data meta-analysis.European heart journal · 2025Pooled it
- Systolic blood pressure time-in-target range and kidney outcomes in patients with hypertension: Findings from the STEP trial.Chinese medical journal · 2026Trial
- Association of Systolic Blood Pressure Time in Target Range With Cardiovascular Events Among PRECISION Participants.Journal of clinical hypertension (Greenwich, Conn.) · 2025Trial
- Time in target range of systolic blood pressure and eGFR slope in patients with type 2 diabetes.Hypertension research : official journal of the Japanese Society of Hypertension · 2025Trial
- Effects of spironolactone on exercise blood pressure in patients at increased risk of developing heart failure: report from the HOMAGE trial.Hypertension research : official journal of the Japanese Society of Hypertension · 2024Trial
- Article
- Intensive blood pressure control in heart failure with preserved ejection fraction: a symptom-modifying strategy.Heart failure reviews · 2026Review
- Time in Target Range of Systolic Blood Pressure and Cardiovascular Disease in Patients with Chronic Kidney Disease: A Korean Nationwide Cohort Study.American journal of nephrology · 2026Article
- Heart Failure and Comorbidities (Chronic Kidney Disease, Diabetes, Obesity) Management: A Multidisciplinary Approach.Cardiorenal medicine · 2026Review
- Development and validation of a deep neural network for predicting coronary heart disease in hypertensive patients using 24-hour ambulatory blood pressure monitoring: a retrospective study.Frontiers in medicine · 2026Article
- A retrospective analysis of systolic blood pressure time in target range among patients in coronary care unit.Scientific reports · 2025Article
- Long-Term Systolic Blood Pressure Time in Target Range and Cardiovascular Disease in Individuals With Hypertension.JACC. Advances · 2025Article
- Association of systolic blood pressure time in target range with carotid atherosclerotic plaque and carotid intima-media thickness in hypertensive patients.Scientific reports · 2025Article
- Systolic blood pressure time in target range within 24 hours and incident heart failure: insights from the real-world setting.Hypertension research : official journal of the Japanese Society of Hypertension · 2025Article
- The association of out-of-office blood pressure time in target range with clinical outcomes.Hypertension research : official journal of the Japanese Society of Hypertension · 2025Article
- Long-Term Time in Target Range for Systolic Blood Pressure Since Childhood and Midlife Arterial Stiffness.JACC. Asia · 2025Article
- Time in target range for systolic blood pressure and glucose with cardiovascular disease and all-cause mortality risks.Hypertension research : official journal of the Japanese Society of Hypertension · 2025Article
- Blood Pressure Levels Within Target: Not Just Good Control But Excellent Control Over Time.JACC. Asia · 2024Article
- Association Between Systolic Blood Pressure Time in Target Range Indices and Adverse Cardiovascular Outcomes.JACC. Advances · 2024Article
- Clinical Update in Heart Failure with Preserved Ejection Fraction.Current heart failure reports · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background The association between blood pressure control and clinical outcomes is unclear among patients with heart failure with preserved ejection fraction. Both too high and too low of systolic blood pressure (SBP) have been reported to be related to poor clinical prognosis. This study aimed to assess the association between time in SBP target range and adverse clinical events among patients with heart failure with preserved ejection fraction. Methods and Results This study was a secondary analysis of the TOPCAT (Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist) trial, a randomized clinical trial that compared the efficacy and safety of spironolactone in patients with heart failure with preserved ejection fraction. Time in target range (TTR) was calculated using linear interpolation, with the target range of SBP defined as 110 to 130 mm Hg. The association between TTR with adverse outcomes was estimated using multivariable Cox regression to adjust for multiple confounders. Participants with greater TTR were younger, more likely to be White, had less comorbidities, and lower body mass index. After adjusting for multiple covariates including mean SBP, 1-SD increment (38.3%) of TTR was significantly associated with a decreased risk of primary composite end point (hazard ratio [HR], 0.81 [0.73-0.90]), as well as a lower risk of all-cause mortality (HR, 0.81 [0.73-0.90]), cardiovascular death (HR, 0.78 [0.68-0.90]), and heart failure hospitalization (HR, 0.85 [0.74-0.97]). Results were similar when participants were categorized by TTR groups. Subgroup analyses showed that the associations were more significant in young people than in the old (
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.